Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 49.6% in February

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 84,500 shares, a decline of 49.6% from the February 13th total of 167,500 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily volume of 432,500 shares, the short-interest ratio is presently 0.2 days.

Theriva Biologics Price Performance

Shares of NYSEAMERICAN:TOVX traded up $0.04 during trading on Friday, reaching $1.15. The company had a trading volume of 38,411 shares, compared to its average volume of 155,790. The company has a market cap of $3.21 million, a price-to-earnings ratio of -0.03 and a beta of 1.22. The firm’s fifty day moving average price is $1.47. Theriva Biologics has a fifty-two week low of $1.03 and a fifty-two week high of $17.11.

Institutional Trading of Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP purchased a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.